As organizations work to bring new therapies to market faster, there is a growing focus on unified and agile development environments that support better collaboration across R&D functions. On the commercial side, companies are aligning strategies and leveraging Veeva tools to improve customer engagement and expand market access. Veeva solutions are also being used to streamline quality processes, ensure product safety, and enable real-time, risk-based decision-making across global operations. With increasingly complex regulatory requirements, life sciences organizations are relying on Veeva to manage data, documents, and workflows in a compliant and auditable way. We provide an overview of these trends and the role of service providers in helping organizations effectively adopt and scale Veeva technologies.
Both demand-side and supply-side trends are covered in our Veeva Services 2025 Market Insights™ and Veeva Services 2025 RadarView™, respectively. These reports present a comprehensive study of Veeva service providers in the life sciences industry, including top trends, analysis, and recommendations. The RadarView also takes a close look at the leaders, innovators, disruptors, and challengers in this market.
We evaluated 63 service providers across three dimensions: practice maturity, partner ecosystem, and investments and innovation. Of the 63 providers, we recognized 11 that brought the most value to the market over the past 12 months.
The reports recognize service providers across four categories:
-
- Leaders: Accenture and Cognizant
- Innovators: HCLTech, Indegene, Infosys, and TCS
- Disruptors: NNIT, Tech Mahindra, and Zensar
- Challengers: Daquma and LTIMindtree
Figure 1 below from the full report illustrates these categories:
“Improving R&D collaboration, streamlining quality processes, and aligning commercial strategies are critical priorities for life sciences firms. As Veeva adoption grows, organizations increasingly look to service providers to support execution and ensure compliance across the ecosystem,” said Rakesh Patro, partner at Avasant.
The reports provide several findings, including the following:
-
- Bringing innovative therapies to market quickly requires unified, agile development platforms that enhance collaboration across R&D processes
- Aligning commercial strategies to boost engagement with customers and expand market access
- Need to streamline quality processes, enhance product safety, and support real-time, risk-based decision-making across global operations
- Stringent global regulations require life sciences companies to manage data, documents, and processes in a compliant, auditable, and consistent manner
“Gen AI is starting to reshape how life sciences organizations use Veeva, improving collaboration in R&D, automating quality reviews, and supporting more effective commercial engagement by delivering timely, compliant content to stakeholders,” said Eratha Poongkuntran, associate director with Avasant.
The RadarView also features detailed profiles of 11 service providers, along with their solutions, offerings, and experience in assisting life sciences enterprises in their digital transformation journeys.
This Research Byte provides a brief overview of Avasant’s Veeva Services 2025 Market Insights™ and Veeva Services 2025 RadarView™ (click for pricing).